Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.…
58,370€
1,41%
Echtzeit-Aktienkurs Incyte Corp.
Bid:
Ask:
Nachrichten zur Incyte Corp. Aktie
FDA Extends INCYs Application for Opzelura Label Expansion
FDA extends review of Incytes ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.…
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
The FDA approves INCYs Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.…
QGEN Stock Rises in After Market Following Partnership With Incyte
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.…
Incyte verkündet FDA-Zulassung von Zynyz® (Retifanlimab-dlwr), die erste und einzige zugelassene Erstlinienbehandlung in den USA für Patienten mit fortgeschrittenem Analkrebs
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass die U.S. Food and Drug Administration (FDA) die Zulassung für Zynyz® (Retifanlimab-dlwr),…
Why Incyte Stock Was Tanking This Week
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past…
Incyte: Still A Buy Despite HS Treatment Data With Povorcitinib
…
INCY Stock Down on Disappointing Skin Disease Study Data
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor…
Stocks making the biggest moves premarket: Affirm, Netflix, Incyte, Norwegian Cruise Line and more
These are the stocks posting the largest moves in premarket trading.…
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.…
Nebulizer Patent Landscape Report 2024: Innovative Developments Fuel Market Growth
Dublin, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The "Nebulizer Patent Landscape Report" report has been added to …
INCYs Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year…
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Streets top -and-bottom-line estimates for Incyte (INCY), review projections for some of its key metrics to gain a…
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe…
Incyte: Multiple Drug Launches Bode Well For Future Growth
…
Aktie von Incyte büßt 1,52 Prozent ein (65,6412 €)
An der US-amerikanischen Börse notiert die Incyte-Aktie aktuell ein wenig leichter. Das Papier notiert zur Stunde bei 68,19 US-Dollar. Am…
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally.…
Incyte reports positive Phase 3 data for Zynyz for lung cancer
…
Incytes Late-stage NSCLC Study Meets Primary and Secondary Goals
INCYs phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer,…
Incyte Aktie: Übernahmefieber - Novartis und andere Pharmariesen im Rennen um Incyte?
Kulmbach (www.aktiencheck.de) - Incyte-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Incyte Corp. (ISIN: US45337C1027,…
Incyte Aktie: Unterbrechung der Studie zu INCB000262
Charlotte (www.aktiencheck.de) - Incyte-Aktienanalyse der Bank of America (BofA):
Die Senkung des Kursziels für die Aktie von Incyte Corp. (ISIN: US45337C1027,…
After-hours movers: Super Micro Computer, Bakkt Holdings, Incyte, and more By Investing.com
After-hours movers: Super Micro Computer, Bakkt Holdings, Incyte, and more…
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Though INCYs performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise…
Kurs von Incyte steigt etwas (59,4900 €)
Das Wertpapier von Incyte notiert am Montag etwas fester. Der jüngste Kurs betrug 66,16 US-Dollar. An der US-amerikanischen Börse hat…
Incyte’s CDK2 Inhibitor INCB123667 zeigt vielversprechende Anzeichen von klinischer Wirkung bei Patienten mit soliden Tumoren in fortgeschrittenem Stadium
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) hat heute neue klinische Daten über INCB123667 bekannt gegeben, einen hochgradig selektiven, potenziellen First-in-Class-CDK2 Inhibitor für…
Incyte gibt positive Topline-Ergebnisse der Pivotalstudie mit Tafasitamab (Monjuvi®) bei rezidiviertem oder refraktärem follikulärem Lymphom bekannt
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) gab heute positive Ergebnisse der zulassungsrelevanten Phase-3-Studie inMIND bekannt, in der die Wirksamkeit und Sicherheit…
Incytes Monjuvi meets primary endpoint in follicular lymphoma phase 3 trial
…
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
On Incytes (INCY) second-quarter 2024 earnings call, investors focus is likely to be on the sales performance of its lead…
Incyte drops as BMO downgrades on $2B buybacks
…
Incyte shares slip after BMO analysts cut rating of drugmaker By Investing.com
Incyte shares slip after BMO analysts cut rating of drugmaker…
Incyte-Aktie legt um 1,33 Prozent zu (59,6756 €)
An der US-amerikanischen Börse liegt der Anteilsschein von Incyte gegenwärtig im Plus. Zuletzt zahlten Investoren für das Wertpapier 64,06 US-Dollar.…
Incyte a new hold at Deutsche Bank as key drugs approach patent cliffs
…
Incyte, Squarespace rise; Chimera Investment, Amazon fall, Monday, 5/13/2024
Stocks that are trading heavily or have substantial price changes on Monday: Incyte, Squarespace rise; Chimera Investment, Amazon fall…
Incyte shares dip after earnings, guidance miss By Investing.com
Incyte shares dip after earnings, guidance miss…
Incyte earnings missed by $0.18, revenue fell short of estimates By Investing.com
Incyte earnings missed by $0.18, revenue fell short of estimates…
Incytes (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incytes (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.…
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.…
Incyte (INCY) to Report Q1 Earnings: Whats in the Cards?
Incytes (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on…
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”…
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
Incytes (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.…